P311, Friend, or Foe of Tissue Fibrosis?

P311 was first identified by the group of Studler et al. (1993) in the developing brain. In healthy, but mainly in pathological tissues, P311 is implicated in cell migration and proliferation. Furthermore, evidence in models of tissue fibrosis points to the colocalization with and the stimulation of...

Descripción completa

Detalles Bibliográficos
Autores principales: Stradiot, Leslie, Mannaerts, Inge, van Grunsven, Leo A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194156/
https://www.ncbi.nlm.nih.gov/pubmed/30369881
http://dx.doi.org/10.3389/fphar.2018.01151
_version_ 1783364180417445888
author Stradiot, Leslie
Mannaerts, Inge
van Grunsven, Leo A.
author_facet Stradiot, Leslie
Mannaerts, Inge
van Grunsven, Leo A.
author_sort Stradiot, Leslie
collection PubMed
description P311 was first identified by the group of Studler et al. (1993) in the developing brain. In healthy, but mainly in pathological tissues, P311 is implicated in cell migration and proliferation. Furthermore, evidence in models of tissue fibrosis points to the colocalization with and the stimulation of transforming growth factor β1 by P311. This review provides a comprehensive overview on P311 and discusses its potential as an anti-fibrotic target.
format Online
Article
Text
id pubmed-6194156
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-61941562018-10-26 P311, Friend, or Foe of Tissue Fibrosis? Stradiot, Leslie Mannaerts, Inge van Grunsven, Leo A. Front Pharmacol Pharmacology P311 was first identified by the group of Studler et al. (1993) in the developing brain. In healthy, but mainly in pathological tissues, P311 is implicated in cell migration and proliferation. Furthermore, evidence in models of tissue fibrosis points to the colocalization with and the stimulation of transforming growth factor β1 by P311. This review provides a comprehensive overview on P311 and discusses its potential as an anti-fibrotic target. Frontiers Media S.A. 2018-10-12 /pmc/articles/PMC6194156/ /pubmed/30369881 http://dx.doi.org/10.3389/fphar.2018.01151 Text en Copyright © 2018 Stradiot, Mannaerts and van Grunsven. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Stradiot, Leslie
Mannaerts, Inge
van Grunsven, Leo A.
P311, Friend, or Foe of Tissue Fibrosis?
title P311, Friend, or Foe of Tissue Fibrosis?
title_full P311, Friend, or Foe of Tissue Fibrosis?
title_fullStr P311, Friend, or Foe of Tissue Fibrosis?
title_full_unstemmed P311, Friend, or Foe of Tissue Fibrosis?
title_short P311, Friend, or Foe of Tissue Fibrosis?
title_sort p311, friend, or foe of tissue fibrosis?
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194156/
https://www.ncbi.nlm.nih.gov/pubmed/30369881
http://dx.doi.org/10.3389/fphar.2018.01151
work_keys_str_mv AT stradiotleslie p311friendorfoeoftissuefibrosis
AT mannaertsinge p311friendorfoeoftissuefibrosis
AT vangrunsvenleoa p311friendorfoeoftissuefibrosis

Ejemplares similares